Zacks Investment Research
02 Sept 2026, 17:46 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
Globus Medical (GMED) is projected to have earnings per share (EPS) growth of 25.3% this year, significantly exceeding the industry average of 12.6%. — Strong projected earnings growth relative to peers is a primary driver for stock price appreciation in growth-oriented equities.
+0.60Globus Medical's sales-to-total-assets (S/TA) ratio is 0.59, slightly above the industry average of 0.58. — Higher asset utilization efficiency is a positive fundamental signal, though the marginal difference from the industry average limits the immediate price impact.
+0.20Globus Medical currently holds a top Zacks Rank and a favorable Growth Score. — Positive proprietary analyst ratings can attract momentum buyers and increase short-term demand for the stock.
+0.20Which stocks this story touches
Continue reading
6 related stories
Top 2 movers · tap to explore
The company is explicitly recommended as a great growth pick with a top Zacks Rank and projected EPS growth that crushes the industry average.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
1h ago
